GlassScriptPhysician profile
Connor Jameson Smith
NPI 1912500109
$5,895.14
in general payments reported to CMS, 2019-2025
27 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,421 · 2022: $3,412 · 2023: $288 · 2024: $433 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,890.40 | 2022 | |
| Team 1, LLC | $1,200.00 | 2021 | |
| Medical Device Business Services, INC. | $409.28 | 2021-2022 | |
| Amgen INC. | $221.98 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $170.25 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $157.74 | 2023-2025 | Camzyos |
| Zimmer Biomet Holdings, INC. | $155.96 | 2022 | |
| Pfizer INC. | $97.19 | 2023-2025 | |
| Pacira Therapeutics, INC. | $74.50 | 2021 | |
| Merck Sharp & Dohme LLC | $72.55 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $61.61 | 2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.87 | 2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $44.05 | 2023-2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $33.81 | 2024 | Arcalyst |
| Smith+Nephew, INC. | $24.79 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $24.26 | 2021 | |
| Bridgebio Pharma, INC. | $23.37 | 2025 | Attruby |
| Cvrx, INC. | $22.41 | 2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.38 | 2023 | Jardiance |
| Medtronic, INC. | $21.04 | 2023 | Linq II |
| Vericel Corporation | $20.90 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $20.00 | 2022 | |
| Altathera Pharmaceuticals LLC | $17.77 | 2024 | Sotalol Hydrochloride |
| Lexicon Pharmaceuticals, INC. | $17.42 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $15.45 | 2023 | Arcalyst |
| Innovation Technologies INC | $15.04 | 2025 | Irrisept |
| Ethicon US, LLC | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.